HERON THERAPEUTICS, INC. /DE/ Payments to Acquire Debt Securities, Available-for-sale
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Payments to Acquire Debt Securities, Available-for-sale of $27.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $14.72M, a 60.23% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $13.14M, a 42.63% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $12.57M, a 1.86% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $6.13M, a 76.11% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for fiscal 2025 was $50.79M, a 50.73% decline from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for fiscal 2024 was $103.09M, a 17.60% increase from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for fiscal 2023 was $87.66M, a 39.83% decline from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire debt securities, available-for-sale for fiscal 2022 was $145.68M, a 12.74% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $27.86M 10-Q · filed 2026-08-10 | $40.43M derived: sum of 3 quarters · filed 2026-08-10 | $46.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $13.14M 10-Q · filed 2026-05-11 | $25.71M derived: sum of 2 quarters · filed 2026-05-11 | $31.84M derived: sum of 3 quarters · filed 2026-05-11 | $41.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.70M derived: sum of 2 quarters · filed 2026-02-26 | $27.88M derived: sum of 3 quarters · filed 2026-08-10 | $50.79M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $15.31M derived: sum of 2 quarters · filed 2026-08-10 | $38.21M 10-Q · filed 2025-11-04 | $50.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $9.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $32.09M 10-Q · filed 2026-08-10 | $44.43M derived: sum of 3 quarters · filed 2026-08-10 | $70.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $22.90M 10-Q · filed 2026-05-11 | $35.24M derived: sum of 2 quarters · filed 2026-05-11 | $60.89M derived: sum of 3 quarters · filed 2026-05-11 | $88.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $12.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.99M derived: sum of 2 quarters · filed 2026-02-26 | $65.19M derived: sum of 3 quarters · filed 2026-02-26 | $103.09M 10-K · filed 2026-02-26 |
| 2024-09-30 | $25.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $52.85M derived: sum of 2 quarters · filed 2025-11-04 | $90.75M 10-Q · filed 2025-11-04 | $114.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $27.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $65.10M 10-Q · filed 2025-08-08 | $88.45M derived: sum of 3 quarters · filed 2026-02-26 | $124.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $37.89M 10-Q · filed 2025-05-06 | $61.24M derived: sum of 2 quarters · filed 2026-02-26 | $97.17M derived: sum of 3 quarters · filed 2026-02-26 | $111.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $23.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.28M derived: sum of 2 quarters · filed 2026-02-26 | $73.72M derived: sum of 3 quarters · filed 2026-02-26 | $87.66M 10-K · filed 2026-02-26 |
| 2023-09-30 | $35.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $50.37M derived: sum of 2 quarters · filed 2024-11-12 | $64.31M 10-Q · filed 2024-11-12 | $82.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $14.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $28.38M 10-Q · filed 2024-08-06 | $46.95M derived: sum of 3 quarters · filed 2025-02-27 | $115.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $13.94M 10-Q · filed 2024-05-07 | $32.51M derived: sum of 2 quarters · filed 2025-02-27 | $100.68M derived: sum of 3 quarters · filed 2025-02-27 | $121.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $18.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $86.74M derived: sum of 2 quarters · filed 2025-02-27 | $107.66M derived: sum of 3 quarters · filed 2025-02-27 | $145.68M 10-K · filed 2025-02-27 |
| 2022-09-30 | $68.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $89.09M derived: sum of 2 quarters · filed 2023-11-14 | $127.11M 10-Q · filed 2023-11-14 | $165.01M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $20.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $58.95M 10-Q · filed 2023-08-14 | $96.84M derived: sum of 3 quarters · filed 2023-08-14 | $126.12M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $38.02M 10-Q · filed 2023-05-11 | $75.92M derived: sum of 2 quarters · filed 2023-05-11 | $105.20M derived: sum of 3 quarters · filed 2023-05-11 | $123.19M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $37.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $67.17M derived: sum of 2 quarters · filed 2023-03-29 | $85.16M derived: sum of 3 quarters · filed 2023-03-29 | $129.22M 10-K · filed 2023-03-29 |
| 2021-09-30 | $29.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $47.26M derived: sum of 2 quarters · filed 2022-11-08 | $91.32M 10-Q · filed 2022-11-08 | $133.29M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $17.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $62.05M 10-Q · filed 2022-08-09 | $104.01M derived: sum of 3 quarters · filed 2022-08-09 | $129.14M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $44.06M 10-Q · filed 2022-05-09 | $86.03M derived: sum of 2 quarters · filed 2022-05-09 | $111.15M derived: sum of 3 quarters · filed 2022-05-09 | $149.14M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $41.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $67.09M derived: sum of 2 quarters · filed 2022-02-28 | $105.08M derived: sum of 3 quarters · filed 2022-02-28 | $134.01M 10-K · filed 2022-02-28 |
| 2020-09-30 | $25.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $63.12M derived: sum of 2 quarters · filed 2021-11-03 | $92.04M 10-Q · filed 2021-11-03 | $281.50M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $37.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $66.92M 10-Q · filed 2021-08-09 | $256.37M derived: sum of 3 quarters · filed 2022-02-28 | $339.59M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $28.92M 10-Q · filed 2021-05-10 | $218.38M derived: sum of 2 quarters · filed 2022-02-28 | $301.60M derived: sum of 3 quarters · filed 2022-02-28 | $378.19M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $189.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $272.68M derived: sum of 2 quarters · filed 2022-02-28 | $349.27M derived: sum of 3 quarters · filed 2022-02-28 | $477.04M 10-K · filed 2022-02-28 |
| 2019-09-30 | $83.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $159.82M derived: sum of 2 quarters · filed 2020-11-05 | $287.58M 10-Q · filed 2020-11-05 | $384.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $76.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $204.36M 10-Q · filed 2020-08-05 | $301.08M derived: sum of 3 quarters · filed 2021-02-24 | $543.58M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $127.76M 10-Q · filed 2020-05-06 | $224.49M derived: sum of 2 quarters · filed 2021-02-24 | $466.98M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | $96.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $339.22M derived: sum of 2 quarters · filed 2021-02-24 | $497.10M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $242.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $400.38M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $157.88M 10-Q · filed 2019-08-05 | |||
| 2017-12-31 | $121.57M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |